Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

• Published in: The New England journal of medicine Vol. 378; no. 25; pp. 2399 - 2410
• Main Authors: Dimopoulos, Meletios A, Tedeschi, Alessandra, Trotman, Judith, García-Sanz, Ramón, Macdonald, David, Leblond, Veronique, Mahe, Beatrice, Herbaux, Charles, Tam, Constantine, Orsucci, Lorella, Palomba, M. Lia, Matous, Jeffrey V, Shustik, Chaim, Kastritis, Efstathios, Treon, Steven P, Li, Jianling, Salman, Zeena, Graef, Thorsten, Buske, Christian
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 21.06.2018
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Arthralgia; Atrial Fibrillation - chemically induced; B-cell lymphoma; Bone marrow; Cancer; CXCR4 protein; Diarrhea; Disease-Free Survival; Female; Fibrillation; Hemoglobin; Hemoglobins - analysis; Hemorrhage; Hospitals; Humans; Hypertension; Immunoglobulin M; Immunoglobulin M - blood; Immunotherapy; Infusions, Intravenous - adverse effects; Inhibitor drugs; Lymphocytes B; Macroglobulinemia; Male; Medical research; Middle Aged; Monoclonal antibodies; MyD88 protein; Nausea; Patients; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; R&D; Research & development; Response rates; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Survival Analysis; Targeted cancer therapy; Waldenstrom Macroglobulinemia - blood; Waldenstrom Macroglobulinemia - drug therapy

A randomized trial comparing ibrutinib plus rituximab with rituximab alone in patients with Waldenström’s macroglobulinemia showed significantly higher rates of progression-free survival and overall response with the addition of ibrutinib.